ESH 2022

2022-06-17 - 2022-06-20
Athen, Greece

EAS 2022

2022-05-22 - 2022-05-25
Milan, Italy

EHRA 2022

2022-04-03 - 2022-04-05
Online, Virtual

ACC 2022

2022-04-02 - 2022-04-04
Online, Virtual

ESC 2021

2021-08-27 - 2021-08-30
Online, Virtual

ACC 2021

2021-05-15 - 2021-05-17
Online, Virtual

ESH-ISH 2021

2021-04-11 - 2021-04-14
Online, Virtual

AHA 2020

2020-11-13 - 2020-11-17
Online, Virtual
Search in Scientific Content:
Date
Filters:
Diagnosis
9:40

Diagnosis and management of primary aldosteronism

Presenter: Paolo Mulatero
Specialty: Hypertension
ESH 2022
Special fo
13:43

Special forms of hypertension, optomized prevention and hypertension epidemiology: Novelties from ESH 2022

Presenter: Gianfranco Parati
Specialty: Hypertension
ESH 2022
Adherence
11:40

Adherence to antihypertensive treatment in patients with CKD: a barrier to optimal renoprotection

Presenter: Michel Burnier
Specialty: Hypertension
ESH 2022
Implementa
16:51

Implementation of the 2019 lipid guidelines: where are we now?

Presenter: Alberico L. Catapano
Specialty: Atherosclerosis
EAS 2022
Diagnosis
9:24

Diagnosis and management of non-adherence in hypertension treatment

Presenter: Jan Václavík
Specialty: Hypertension
ESH 2022
Nocturnal
7:43

Nocturnal hypertension

Presenter: Paolo Palatini
Specialty: Hypertension
ESH 2022
Blood pres
12:25

Blood pressure management in older frail patients

Presenter: Athanase Benetos
Specialty: Hypertension
ESH 2022
Lifelong b
11:22

Lifelong burden of hypertension

Presenter: Giuseppe Mancia
Specialty: Hypertension
ESH 2022
Novelties
9:16

Novelties in the diagnosis and management of primary aldosteronism

Presenter: Constantine Stratakis
Specialty: Hypertension
ESH 2022
Detecting
7:38

Detecting elevated lipoprotein(a) and addressing the ASCVD risks

Presenter: Florian Kronenberg
Specialty: Atherosclerosis
EAS 2022
Who needs
6:58

Who needs injectable therapies for cholesterol lowering or statins and ezetimibe are enough for CVD prevention?

Presenter: Carl Orringer
Specialty: Atherosclerosis
EAS 2022
The differ
2:47

The difference between the genetic and pharmacological inhibition of PCSK9

Presenter: Giuseppe Danilo Norata
Specialty: Atherosclerosis
EAS 2022
ESC/EAS jo
10:13

ESC/EAS joint session: What is new in secondary CV prevention?

Presenter: Ulrich Laufs
Specialty: Atherosclerosis
EAS 2022
ESC/EAS jo
6:38

ESC/EAS joint session: Advances in CV risk estimation with focus on dyslipidemia

Presenter: Ian Graham
Specialty: Atherosclerosis
EAS 2022
Atrial fib
19:010

Atrial fibrillation guidelines into clinical practice

Presenter: Daniel Scherr
EHRA 2022
Recent dev
7:02

Recent developments of the conduction system pacing

Presenter: Hung-Fat Tse
EHRA 2022
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
HOPE 4 - I
5:19

HOPE 4 - Impact on cardiovascular risk of a community based multifaceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study

Presenter: J.D. Schwalm
SYNTAXES:
7:28

SYNTAXES: Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention: The SYNTAX Extended Survival study

Presenter: Daniel Johannes Franciscus Maria Thuijs
MITRA-FR -
8:46

MITRA-FR - 2 years follow-Up of the MITRA-FR study a randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation

Presenter: Jean-Francois Obadia
DAPA HF Th
6:20

DAPA HF The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

Presenter: John McMurray
CONDI-2/ER
4:010

CONDI-2/ERIC-PPCI Effect of remote ischemic conditioning on clinical outcomes in patients with Stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Presenter: Hans Erik Botker
Treatment
3:27

Treatment of iron deficiency in acute and chronic heart failure

Presenter: Piotr Ponikowski
Alcohol se
6:32

Alcohol septal ablation in hypertrophic cardiomyopathy: past and future

Presenter: Hubert Seggewiss
The use of
3:35

The use of SGLT2 inhibitors in the prevention and treatment of heart failure

Presenter: Petar M. Seferovic
Direct myo
5:15

Direct myosin inhibitors in hypertrophic cardiomyopathy: a new era?

Presenter: Iacopo Olivotto
Liraglutid
13:26

Liraglutide for Weight Management in the Real World

Presenter: Roman Vangoitsenhoven
The role o
10:22

The role of GLP-1 receptor agonists in weight reduction and cardiovascular risk reduction

Presenter: Michael A. Nauck
Clinical I
8:59

Clinical Impact of Liraglutide as a Treatment of Obesity

Presenter: Alexander Miras